MarginProbe(R) Post-market Study Presented at San Antonio Breast Cancer Symposium

MarginProbe Use Reduces Re-excision Surgeries in Patients With DCIS

        Print
| Source: Dune Medical Devices

WESTBOROUGH, Mass., Jan. 6, 2014 (GLOBE NEWSWIRE) -- An analysis of the MarginProbe post-market study of patients with ductal carcinoma in situ (DCIS) conducted in 3 centers in Germany was presented during the 2013 CTRC-AACR San Antonio Breast Cancer Symposium. The results were presented by Dr. Marc Thill, Head of the Department of Gynecology and Obstetrics and the Breast Cancer Center at Agaplesion Markus Hospital, Frankfurt. In patients with DCIS, adjunctive use of MarginProbe significantly improved surgical outcomes by increasing surgeons' ability to identify and immediately resect positive margins, reducing the number of patients requiring re-excision by over 50%.

"DCIS is a significant challenge to the breast surgeon," said Dr. Thill. "Currently available techniques are of little help in patients with DCIS, and these patients face very high re-excision rates, up to 40%, as reported in the literature. By incorporating MarginProbe, we have been able to offer our patients a better option with a significantly lower risk of additional surgery."

"Since the early days of developing this product we aimed to include DCIS patients, within the target set of patients who can benefit from the MarginProbe, alongside IDC patients. These results are consistent with previous DCIS related experiences with MarginProbe, and represent a significant step forward for surgeons and their patients with DCIS. By improving the identification of positive margins with the MarginProbe System, surgeons have been able to offer a better surgical treatment," said Dan Hashimshony, Founder and CEO of Dune Medical Devices. "This is a big step forward for breast cancer patients."

About Dune Medical Devices

Dune Medical Devices was founded in 2002 by Dr. Dan Hashimshony to realize the extraordinary medical potential of its proprietary tissue characterization technology. Offering surgeons and radiologists the real time ability to identify cancerous tissues and react immediately, this technology holds the promise for a broad range of surgical and diagnostic applications.

Dune Medical Devices is a privately held company with offices in the U.S. and Israel. For more information, please visit www.dunemedical.com

Michael Graffeo
Vice President Marketing & Sales
Dune Medical Devices
508-620-2782 /